Sebi flags Dabur India over delayed FDA warning letter disclosure

The Securities and Exchange Board of India (Sebi) has cautioned Dabur India Limited over the delayed disclosure of a warning letter issued by the United States Food and Drug Administration (USFDA), marking a fresh regulatory scrutiny of the consumer goods company's compliance practices.

The market regulator noted that Dabur's tardiness in communicating the USFDA warning to stock exchange authorities and investors constituted a breach of mandatory disclosure norms. Listed companies are required to promptly inform the exchanges and the market of material developments that could influence investment decisions.

Sebi's notice emphasized that such lapses in compliance with disclosure requirements could invite enforcement action under its regulations. The regulator did not specify the contents of the USFDA warning letter or the nature of concerns that prompted the American health authority's communication to the company.

The warning underscores heightened regulatory oversight of India's listed companies regarding their adherence to stock market disclosure rules. Dabur India, a major player in the FMCG sector with operations spanning personal care, foods, and pharmaceuticals, did not immediately respond to requests for comment on the Sebi directive.

The incident serves as a reminder to Indian corporates about the critical importance of timely and transparent communication with market authorities, particularly when dealing with regulatory matters from international bodies that could have material implications for shareholders and stakeholders.